SCHEMBL57316

SCHEMBL57316

O=[N+]([O-])c1cnc(Cl)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
MAPK1 P28482 1/20 0.48
ALDH1A1 P00352 5/20 0.43
CYP3A4 P08684 1/20 0.43
TDP1 Q9NUW8 3/20 0.41
GPR35 Q9HC97 2/20 0.40
PGK1 P00558 1/20 0.39
VCAM1 P19320 2/20 0.39
MAPT P10636 2/20 0.39
DHFR P00374 1/20 0.39
AHR P35869 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29467181 1.00 TSHR (0.48) TSHRMAPK1ALDH1A1CYP3A4TDP1
SCHEMBL12489778 0.83 TSHR (0.44) TSHRMAPK1ALDH1A1CYP3A4TDP1
SCHEMBL32681751 0.82 TSHR (0.42) TSHRMAPK1ALDH1A1CYP3A4TDP1
SCHEMBL17512681 0.80 TDP1 (0.46) TSHRMAPK1ALDH1A1CYP3A4TDP1
SCHEMBL15270693 0.80 ALDH1A1 (0.44) TSHRMAPK1ALDH1A1CYP3A4TDP1
SCHEMBL381803 0.80 ALDH1A1 (0.49) TSHRMAPK1ALDH1A1CYP3A4GPR35
SCHEMBL563628 0.80 TDP1 (0.46) TSHRALDH1A1CYP3A4TDP1MAPT
SCHEMBL17506477 0.80 AAK1 (0.40) TSHRMAPK1ALDH1A1CYP3A4TDP1
SCHEMBL29390182 0.80 ALDH1A1 (0.49) TSHRMAPK1ALDH1A1CYP3A4GPR35
SCHEMBL619628 0.80 TSHR (0.46) TSHRMAPK1ALDH1A1CYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113493436-B Amino substituted pyridine derivative and preparation method thereof, pharmaceutical composition and application 中国医学科学院药物研究所 2023-10-20 CN claimed
CN-113493436-A Amino-substituted pyridine derivative and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2021-10-12 CN claimed
US-20260098028-A1 Compounds and Their Use for Treatment of Hemoglobinopathies BRISTOL-MYERS SQUIBB COMPANY (US) 2026-04-09 US disclosed
US-20260062427-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORP (US) 2026-03-05 US disclosed
EP-4698544-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2026-02-25 EP disclosed
US-20260049093-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORP (US) 2026-02-19 US disclosed
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2026-02-17 US disclosed
US-20260042781-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORP (US) 2026-02-12 US disclosed
EP-4680607-A1 BICYCLIC UREAS AS KINASE INHIBITORS Incyte Corporation (US) 2026-01-21 EP disclosed
EP-4225739-B1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
US-12528791-B2 Thyroid hormone receptor beta agonist compounds TERNS PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
EP-1490367-A1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-29 EP disclosed
WO-2004076454-A1 DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) 2004-09-10 WO disclosed
US-20040176380-A1 New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) 2004-09-09 US disclosed
WO-2004014384-A2 CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
WO-2003080610-A1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-10-02 WO disclosed
EP-0400583-B1 Imidazoquinoxalinones, their aza analogs and process for their preparation BERLEX LAB (US) 1999-11-17 EP disclosed
US-5166344-A Process for the preparation of imidazoquinoxalinones BERLEX LABORATORIES, INC. (US) 1992-11-24 US disclosed
US-5055465-A IMIDAZOQUINOXALINONES, THEIR AZA ANALOGS AND PROCESS FOR THEIR PREPARATION BERLEX LABORATORIES, INC. (US) 1991-10-08 US disclosed
EP-0400583-A1 Imidazoquinoxalinones, their aza analogs and process for their preparation BERLEX LABORATORIES, INC. (US) 1990-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049093-A1 Bicyclic Ureas As Kinase Inhibitors OXSR1, JAK1, NCOR1 TSHR 157/4885MAPK1 28/4885ALDH1A1 1726/4885
US-20040176380-A1 New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions QDPR, DHPS, DRD5 TSHR 3992/4885MAPK1 3107/4885ALDH1A1 608/4885
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 TSHR 1671/4885MAPK1 899/4885ALDH1A1 1935/4885
US-12528791-B2 Thyroid hormone receptor beta agonist compounds THRB, THRA, TSHR TSHR 3/4885MAPK1 2095/4885ALDH1A1 2577/4885
US-20260042781-A1 Bicyclic Ureas As Kinase Inhibitors NR0B1, NR2C2, ERBB2 TSHR 226/4885MAPK1 68/4885ALDH1A1 2073/4885
US-20260062427-A1 Bicyclic Ureas As Kinase Inhibitors OXSR1, NCOR1, NR0B1 TSHR 106/4885MAPK1 32/4885ALDH1A1 2038/4885
US-20260098028-A1 Compounds and Their Use for Treatment of Hemoglobinopathies HBZ, HBG2, HBB TSHR 2323/4885MAPK1 4218/4885ALDH1A1 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.